Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates

分组1 - Catalent reported quarterly earnings of $0.65 per share, exceeding the Zacks Consensus Estimate of $0.46 per share, and showing a significant increase from $0.09 per share a year ago, resulting in an earnings surprise of 41.30% [1] - The company achieved revenues of $1.3 billion for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 5.37%, compared to $1.07 billion in the same quarter last year [2] - Catalent's stock has increased by approximately 33.1% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] 分组2 - The earnings outlook for Catalent is mixed, with the current consensus EPS estimate for the upcoming quarter at $0.03 on revenues of $1.01 billion, and $1.17 on revenues of $4.58 billion for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 39% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]